BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Malaguarnera M, Restuccia S, Di Fazio I, Zoccolo AM, Ferlito L, Bentivegna P. Serum carnitine levels in chronic hepatitis C patients before and after lymphoblastoid interferon-alpha treatment. BioDrugs. 1999;12:65-69. [PMID: 18031163 DOI: 10.2165/00063030-199912010-00007] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
Number Citing Articles
1 Bazotte RB, Lopes-bertolini G. Effects of oral L-carnitine and DL-carnitine supplementation on alloxan-diabetic rats. Braz arch biol technol 2012;55:81-8. [DOI: 10.1590/s1516-89132012000100010] [Cited by in Crossref: 11] [Article Influence: 1.1] [Reference Citation Analysis]
2 Jansen L, de Niet A, Stelma F, van Iperen EP, van Dort KA, Plat-sinnige MJT, Takkenberg RB, Chin DJ, Zwinderman A(, Lopatin U, Kootstra NA, Reesink HW. HBsAg loss in patients treated with peginterferon alfa-2a and adefovir is associated with SLC16A9 gene variation and lower plasma carnitine levels. Journal of Hepatology 2014;61:730-7. [DOI: 10.1016/j.jhep.2014.05.004] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
3 Malaguarnera M, Maugeri D, Saraceno B, Romano M, Neri S, Rapisarda R, Pistone G. Effects of Carnitine on Biochemical Responses in Patients with Chronic Hepatitis C Treated with Interferon-??: . Clinical Drug Investigation 2002;22:443-8. [DOI: 10.2165/00044011-200222070-00004] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
4 Nassiri A, Dashti-khavidaki S, Khalili H, Nassiri-toosi M, Abdollahi A. Serum carnitine level and its associated factors in patients with chronic viral hepatitis. Future Virology 2014;9:373-83. [DOI: 10.2217/fvl.14.10] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
5 Malaguarnera M, Vacante M, Giordano M, Motta M, Bertino G, Pennisi M, Neri S, Malaguarnera M, Volti GL, Galvano F. L-carnitine supplementation improves hematological pattern in patients affected by HCV treated with Peg interferon-α 2b plus ribavirin. World J Gastroenterol 2011; 17(39): 4414-4420 [PMID: 22110268 DOI: 10.3748/wjg.v17.i39.4414] [Cited by in CrossRef: 28] [Cited by in F6Publishing: 28] [Article Influence: 2.5] [Reference Citation Analysis]
6 Hatamkhani S, Khalili H, Karimzadeh I, Abdollahi A, Jafari S, Khazaeipour Z. Carnitine deficiency and its possible risk factors in TB patients: first report. Immunotherapy 2013;5:945-53. [PMID: 23998730 DOI: 10.2217/imt.13.90] [Reference Citation Analysis]
7 Ringseis R, Grundmann SM, Schuchardt S, Most E, Eder K. Limited Impact of Pivalate-Induced Secondary Carnitine Deficiency on Hepatic Transcriptome and Hepatic and Plasma Metabolome in Nursery Pigs. Metabolites 2021;11:573. [PMID: 34564388 DOI: 10.3390/metabo11090573] [Reference Citation Analysis]